Boehringer Ingelheim today announced new data from the global Phase III FIBRONEER™ program on nerandomilast, an investigational oral preferential PDE4B inhibitor, which is currently not approved for use. The new pooled analyses, the first to demonstrate a nominally significant reduction in risk
